Evaxion Announces Publication Of Data From Phase 1 Dose Escalation Study Of EVX-01 In 'Journal for ImmunoTherapy of Cancer,' Demonstrating 67% Objective Response Rate
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech announced the publication of data from its Phase 1 dose escalation study of EVX-01 in the 'Journal for ImmunoTherapy of Cancer,' showing a 67% objective response rate.
June 17, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech's publication of Phase 1 data for EVX-01 in a reputable journal, showing a 67% objective response rate, is likely to positively impact the stock price in the short term.
The publication in a reputable journal and the high response rate of 67% are significant positive indicators for the success of EVX-01, likely boosting investor confidence and driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100